Cargando…

Assessment of harms, benefits, and cost‐effectiveness of prostate cancer screening: A micro‐simulation study of 230 scenarios

BACKGROUND: Prostate cancer screening incurs a high risk of overdiagnosis and overtreatment. An organized and age‐targeted screening strategy may reduce the associated harms while retaining or enhancing the benefits. METHODS: Using a micro‐simulation analysis (MISCAN) model, we assessed the harms, b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Getaneh, Abraham M., Heijnsdijk, Eveline A. M., Roobol, Monique J., de Koning, Harry J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Cancer Prevention
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7571827/ https://www.ncbi.nlm.nih.gov/pubmed/32813910 http://dx.doi.org/10.1002/cam4.3395

Ejemplares similares

Cost‐effectiveness of multiparametric magnetic resonance imaging and MRI‐guided biopsy in a population‐based prostate cancer screening setting using a micro‐simulation model
por: Getaneh, Abraham M., et al.
Publicado: (2021)

Screening for cancers with a good prognosis: The case of testicular germ cell cancer
por: Heijnsdijk, Eveline A. M., et al.
Publicado: (2021)

Finding the optimal mammography screening strategy: A cost‐effectiveness analysis of 920 modelled strategies
por: Kregting, Lindy M., et al.
Publicado: (2022)

All‐cause mortality versus cancer‐specific mortality as outcome in cancer screening trials: A review and modeling study
por: Heijnsdijk, Eveline A. M., et al.
Publicado: (2019)

Comparison of biopsy under‐sampling and annual progression using hidden markov models to learn from prostate cancer active surveillance studies
por: Li, Weiyu, et al.
Publicado: (2020)

The potential of breast cancer screening in Europe
por: Zielonke, Nadine, et al.
Publicado: (2020)

Treatment of local–regional prostate cancer detected by PSA screening: benefits and harms according to prognostic factors
por: Wever, E M, et al.
Publicado: (2013)

Systematic reviews as a ‘lens of evidence’: Determinants of benefits and harms of breast cancer screening
por: Mandrik, Olena, et al.
Publicado: (2019)

Prostate-Specific Antigen Screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer–Rotterdam
por: Wever, Elisabeth M., et al.
Publicado: (2010)

The comparative effectiveness of mpMRI and MRI-guided biopsy vs regular biopsy in a population-based PSA testing: a modeling study
por: Getaneh, Abraham M., et al.
Publicado: (2021)

Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer
por: Heijnsdijk, E A M, et al.
Publicado: (2009)

Evaluating the clinical trends and benefits of low‐dose computed tomography in lung cancer patients
por: Qiao, Edmund M., et al.
Publicado: (2021)

Long‐term health‐related quality of life among men with prostate cancer in the Finnish randomized study of screening for prostate cancer
por: Talala, Kirsi, et al.
Publicado: (2020)

Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen
por: Vickers, Andrew J, et al.
Publicado: (2014)

Lifetime Benefits and Harms of Prostate-Specific Antigen–Based Risk-Stratified Screening for Prostate Cancer
por: Heijnsdijk, Eveline A M, et al.
Publicado: (2020)

Extending Age Ranges in Breast Cancer Screening in Four European Countries: Model Estimations of Harm-to-Benefit Ratios
por: Zielonke, Nadine, et al.
Publicado: (2021)

Waist circumference and a body shape index and prostate cancer risk and mortality
por: Jochems, Sylvia H. J., et al.
Publicado: (2021)

BMI trajectories and risk of overall and grade‐specific prostate cancer: An observational cohort study among men seen for prostatic conditions
por: Wang, Kai, et al.
Publicado: (2018)

Metformin reduces prostate cancer risk among men with benign prostatic hyperplasia: A nationwide population‐based cohort study
por: Kuo, Yu‐Jui, et al.
Publicado: (2019)

Tobacco smoking, polymorphisms in carcinogen metabolism enzyme genes, and risk of localized and advanced prostate cancer: results from the California Collaborative Prostate Cancer Study
por: Shahabi, Ahva, et al.
Publicado: (2014)

Prostate cancer survivors: Risk and mortality in second primary cancers
por: Chattopadhyay, Subhayan, et al.
Publicado: (2018)

Depression and prostate cancer risk: A Mendelian randomization study
por: Chen, Xiong, et al.
Publicado: (2020)

Testicular self-examination and testicular cancer: a cost-utility analysis
por: Aberger, Michael, et al.
Publicado: (2014)

Personalized strategies in population screening for prostate cancer
por: Remmers, Sebastiaan, et al.
Publicado: (2020)

Associations of multimorbidity and patient‐reported experiences of care with conservative management among elderly patients with localized prostate cancer
por: Fiano, Ryan M., et al.
Publicado: (2020)

Surgery shows survival benefit in patients with primary intestinal diffuse large B‐cell lymphoma: A population‐based study
por: Wang, Moran, et al.
Publicado: (2021)

AST/ALT ratio as a significant predictor of the incidence risk of prostate cancer
por: Zhou, Jiatong, et al.
Publicado: (2020)

Associations between prostate cancer‐related anxiety and health‐related quality of life
por: Erim, Daniel O., et al.
Publicado: (2020)

Prostate cancer risk in patients with melanoma: A systematic review and meta‐analysis
por: Acharya, Prakash, et al.
Publicado: (2020)

Association between PSA values and surveillance quality after prostate cancer surgery
por: Chapman, Christina Hunter, et al.
Publicado: (2019)

External beam radiotherapy for prostate cancer: What are the current research trends and hotspots?
por: Li, Rui, et al.
Publicado: (2021)

Long‐term quality of life after definitive treatment for prostate cancer: patient‐reported outcomes in the second posttreatment decade
por: Jang, Joanne W., et al.
Publicado: (2017)

Systematic reviews as a “lens of evidence”: Determinants of cost‐effectiveness of breast cancer screening
por: Mandrik, Olena, et al.
Publicado: (2019)

Racial differences in patterns of treatment among men diagnosed with de novo advanced prostate cancer: A SEER‐Medicare investigation
por: Beebe‐Dimmer, Jennifer L., et al.
Publicado: (2019)

Part I: cancer in Sudan—burden, distribution, and trends breast, gynecological, and prostate cancers
por: Elamin, Amany, et al.
Publicado: (2015)

Recent decline in prostate cancer incidence in the United States, by age, stage, and Gleason score
por: Herget, Kimberly A., et al.
Publicado: (2015)

Difference in prostate cancer incidence around sixty years: effects of age and metabolic diseases
por: Choi, Jin Bong, et al.
Publicado: (2018)

Body mass index trajectories and prostate cancer risk: Results from the EPICAP study
por: Lavalette, Céline, et al.
Publicado: (2020)

Race, tumor location, and disease progression among low‐risk prostate cancer patients
por: Mygatt, Justin G., et al.
Publicado: (2020)

Estimated annual prevalence, medical service utilization and direct costs of lung cancer in urban China
por: Zhu, Dawei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mq1dengfcu8nhp6du2a7bntfp5